About 1 000 reports

  • GASTROINTESTINAL THERAPEUTICS MARKET, GLOBAL, CLINICAL TRIAL DURATION BY
  • shows that, when gastrointestinal clinical trials are segmented by molecular target,

Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape Summary Gastrointestinal disorders are common, and a number of them have a large patient population. Across the seven major markets (the US, the UK, France,...

  • Clinical Research
  • World
  • Market Size
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Musculoskeletal Drugs was the largest segment in the region market at 15.5% of the market worth about $6.4 billion.

Drugs For Respiratory Diseases P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A

  • Clinical Research
  • Dermatological Treatment
  • Managed Care
  • Respiratory Monitoring
  • Market Size

ipage=##& xml=##& quest=##& rid=##& section=##& sequence=-##& pdf=##& dn=## [Accessed February ##, 2017].

  • Clinical Research
  • Dermatological Treatment
  • Managed Care
  • Pfizer Inc.
  • Roche Group

GLP-## agonists have been associated with a common side effect of gastrointestinal disturbances such as nausea and vomiting, which can reduce patient compliance (Prasad-Reddy and Isaacs, 2015).

  • Clinical Research
  • World
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Eli Lilly & Co.
  • OPPORTUNITIES

TABLE ##.

  • Clinical Research
  • Managed Care
  • World
  • Forecast
  • Market Size
  • Porter's Five Forces Analysis

Phase ## and Phase ##, then phase ## WHICH ONE IS THE FASTEST GROWING?

  • Clinical Research
  • World
  • Forecast
  • Market Size
  • Supply
  • Porter's Five Forces Analysis

Phase ## and Phase ##, then phase ## WHICH ONE IS THE FASTEST GROWING?

  • Clinical Research
  • World
  • Forecast
  • Market Size
  • Supply

Additionally, as CF is a multi-system disease pancreatic, gastrointestinal and reproductive problems will remain even if the lung transplant is successful.

  • Clinical Research
  • World
  • Market Size
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.

Particularly PDE-## and PDL-## inhibitors, the market is huge.

  • Clinical Research
  • Dermatological Treatment
  • Managed Care
  • World
  • Forecast
  • ORPHAN AND RARE DERMATOLOGY DRUGS MARKET, GLOBAL, APPROVED ORPHAN AND
  • 3.3 Highly Genericized Drugs

Stomach tests involve endoscopies (a popular technique to visualize internal body cavities) and gastrointestinal biopsies (taking a sample from inside the patient' s gastrointestinal tract for analysis).

  • Clinical Research
  • Dermatological Treatment
  • World
  • AbbVie Inc.
  • Amryt Pharma plc

Grade ## hypertension (##% vs ##%), proteinuria (##% vs ##%), arterial thromboembolic events (##% vs ##%), and gastrointestinal perforation (##% vs ##%) were more commonly observed in the bevacizumab plus mIFL group than in the mIFL group.

  • Cancer
  • Clinical Research
  • Dermatological Treatment
  • Managed Care
  • Merck & Co., Inc.

All treatment regimens were well tolerated, with a similar incidence of upper gastrointestinal (GI) AEs.

  • Chronic Disease
  • Clinical Research
  • Dermatological Treatment
  • Managed Care
  • Amgen Inc.

Minor AEs such as stomatitis, headaches, fatigue and gastrointestinal problems such as nausea and vomiting may occur when using Metolate.

  • Clinical Research
  • Dermatological Treatment
  • World
  • AbbVie Inc.
  • Allergan plc
  • Lymphom a

Other symptoms include retrosternal pain, weight loss, hematemesis (vomiting blood) and melena (black feces associated with gastrointestinal hemorrhage).

  • Clinical Research
  • Managed Care
  • World
  • AbbVie Inc.
  • Aduro BioTech, Inc.
  • RA Therapeutics Market, Competitor Matrix for RA Marketed and Pipeline Products, 2017

Biologics are susceptible to metabolism in the gastrointestinal tract and lack permeability, which collectively leads to poor bioavailability.

  • Clinical Research
  • Dermatological Treatment
  • AbbVie Inc.
  • Galapagos NV
  • Pfizer Inc.

Gastrointestinal Cancer Research; ##(##): ##-## Mayo Clinic (2014).

  • Clinical Research
  • Dermatological Treatment
  • Managed Care
  • World
  • Janssen Biotech, Inc.

The ACURATE family of valve products is one of two valve systems in the Boston Scientific structural heart portfolio.

  • Clinical Research
  • Prosthesis
  • United States
  • Edwards Lifesciences Corporation
  • Valtech Cardio, Ltd.
  • 8.2 ALL PIPELINE DRUGS BY PHASE

DURING CHILDHOOD, ASTHMA IS MORE COMMON IN MALES, WITH A MALE-TO-FEMALE RATIO OF ##:## UP TO PUBERTY, WHEN IT CHANGES TO ##:##.

  • Clinical Research
  • Dermatological Treatment
  • Respiratory Monitoring
  • World
  • Market Size

As such, non-selective COX inhibitors typically produce COX-## inhibitory gastrointestinal (GI) side effects, including gastric ulceration, bleeding and perforation.

  • Clinical Research
  • World
  • Market Size
  • Allergan plc
  • Amgen Inc.

Heparin is given intravenously due to poor gastrointestinal tract absorbability.

  • Clinical Research
  • Dermatological Treatment
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Clinical Trials by E7 Countries: Proportion of Functional (Non Ulcer) Dyspepsia to Gastrointestinal Clinical Trials
  • Clinical Trials by G7 Countries: Proportion of Functional (Non Ulcer) Dyspepsia to Gastrointestinal Clinical Trials

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H1, 2015" provides data on the Functional (Non Ulcer) Dyspepsia clinical trial scenario. This report provides elemental information and data...

  • Clinical Research
  • World
  • Actavis plc
  • Astellas Pharma Inc.
  • Zeria Pharmaceutical Co., Ltd.

When gastrointestinal AEs were reported their intensity was much lower than with oxycodone.

  • Clinical Research
  • World
  • Amgen Inc.
  • Daiichi Sankyo Company
  • Eli Lilly & Co.
  • Ph ase I
  • Pharmaceutical Industry, Clinical Trial Duration in Phase I by Therapy Area, 2006-

Health Affairs; ##(##): ##-## Vernon J, et al. (2010).

  • Clinical Research
  • Pharmaceutical
  • Therapy
  • United States
  • Market Size
  • Uveitis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of Uveitis

Indian Journal of Ophthalmology; ##(##): ## Pfizer.

  • Clinical Research
  • Dermatological Treatment
  • World
  • Forecast
  • Market Size

GLP-## IS AN INCRETIN HORMONE THAT IS RELEASED FROM CELLS IN THE GASTROINTESTINAL TRACT INTO THE CIRCULATION IN RESPONSE TO INGESTED NUTRIENTS FROM FOOD.

  • Clinical Research
  • Managed Care
  • Southeast Asia
  • Novo Nordisk Group
  • Sanofi S.A.

Report Title Published Date ##.

  • Clinical Research
  • Managed Care
  • North America
  • United States
  • Horizon Discovery

The Pharma Innovation; ##(##): ##-## Bresnick GH (1983).

  • Clinical Research
  • Dermatological Treatment
  • World
  • Adverum Biotechnologies, Inc.
  • Alcon, Inc.
  • LINZESS: CURRENT STATUS OF DEVELOPMENT
  • 8.3.7. CLINICAL STUDIES

DIGESTIVE AND GASTROINTESTINAL DISORDERS DIGESTIVE AND GASTROINTESTINAL DISORDERS ARE ONE OF THERAPEUTIC AREAS THAT ARE TARGETED BY SEVERAL ORAL PEPTIDE / PROTEIN THERAPEUTICS THAT ARE EITHER MARKETED OR UNDER DEVELOPMENT.

  • Clinical Research
  • North America
  • United States
  • Ironwood Pharmaceuticals, Inc.
  • Novo Nordisk Group

IMRT HAS HELPED TO DECREASE THE OCCURRENCE OF GASTROINTESTINAL (GI) TOXICITIES USUALLY ASSOCIATED WITH EBRT.

  • Clinical Research
  • Managed Care
  • Prostate Cancer
  • Therapy
  • PROVENGE group

Overall, there was one serious adverse event of moderate gastrointestinal infection that was determined by the investigator not to be drugrelated.

  • Clinical Research
  • Managed Care
  • World
  • Market Size
  • Pharming Group NV